The arabin pessary to prevent preterm birth in women with a twin pregnancy and a short cervix : The STOPPIT 2 RCT
| dc.contributor.author | on behalf of the STOPPIT collaborative group | |
| dc.contributor.institution | University of Aberdeen.Centre for Healthcare Randomised Trials (CHaRT) | en |
| dc.contributor.institution | University of Aberdeen.Aberdeen Centre for Evaluation | en |
| dc.contributor.institution | University of Aberdeen.Institute of Applied Health Sciences | en |
| dc.date.accessioned | 2021-08-26T20:23:01Z | |
| dc.date.available | 2021-08-26T20:23:01Z | |
| dc.date.issued | 2021-07-01 | |
| dc.description | Funding Information: The research reported in this issue of the journal was funded by the HTA programme as project number 13/04/22. The contractual start date was in November 2014. The draft report began editorial review in September 2020 and was accepted for publication in February 2021. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report. Declared competing interests of authors: Jane E Norman has received grants from government and charitable bodies for research into understanding the mechanism of term and preterm labour and understanding treatments. Within the last 3 years, Jane E Norman has acted on a Data Safety and Monitoring Board for a study involving a preterm birth therapeutic agent for GlaxoSmithKline plc (GlaxoSmithKline plc, Brentford, UK) and has provided consultancy for a small pharmaceutical company (Dilafor AB, Solna, Sweden) on drugs to alter labour progress. She was on the Health Technology Assessment (HTA) Maternal Neonatal and Child Health Panel (2013–18) and she was a member of the National Institute for Health Research (NIHR) HTA and Efficacy and Mechanism Evaluation (EME) Editorial Board (2012–14). John Norrie reports grants from the University of Edinburgh (Edinburgh, UK) during the conduct of the study, and declares that he is or has been a member of the following: HTA Commissioning Sub-Board (EOI) (2012–16), NIHR CTU Standing Advisory Committee (2017–present), NIHR HTA and EME Editorial Board (2014–19), Pre-Exposure Prophylaxis Impact Review Panel (2017–present), EME Strategy Advisory Committee (2019–present), EME – Funding Committee Members (2019–present), EME Funding Committee Sub-Group Remit & Comp Check (2019–present), HTA General Committee (2016–19), HTA Funding Committee Policy Group (formerly Clinical Studies Group) (2016–19), HTA Commissioning Committee (2010–16) and was a member of the HTA and EME Editorial Board between 2014 and 2019. Sarah Cunningham-Burley reports personal fees and other from the Wellcome Trust (London, UK), other from the University of Copenhagen (Copenhagen, Denmark), other funding from NIHR Global Health Research, personal fees from the French National Cancer Institute (Paris, France) and personal fees from the Health Research Board (Dublin, Ireland), outside the submitted work. Andrew Shennan is a member of the NIHR HTA Commissioning Committee (2018–22). Stephen C Robson was a member of the NIHR EME Funding Committee (2012–15). Steven Thornton is a trustee of a number of charities, including those that fund related research. He reports personal fees from GlaxoSmithKline plc, during the conduct of the study and outside the submitted work, and personal fees from Johnson & Johnson (Johnson & Johnson, Brunswick, NJ, USA) for consulting services. He holds positions in the Royal College of Obstetricians and Gynaecologists (London, UK) and other organisations. He was a member of the NIHR EME Strategy Advisory Committee (2018–19), EME – Funding Committee Members (2015–19), EME Funding Committee Sub-Group Remit & Comp Check (2018–19) and the Medical Research Council Multimorbidity Board (2020). Neil Marlow reports personal fees from Shire-Takeda (London, UK), Novartis Pharmaceuticals UK Ltd (London, UK) and GlaxoSmithKlein plc, outside the submitted work. Sarah J Stock declares that she is a member of the NIHR HTA General Committee (2016–22). In addition, Sarah J Stock received other research funding from the NIHR (14/32/01 QUIDS), Wellcome Trust (209560/Z/17/Z) and Chief Scientist Office (Edinburgh, UK), during the course of the study. Philip R Bennett reports personal fees and membership of a scientific panel from ObsEva (Plan-les-Ouates, Switzerland), outside the submitted work. In addition, Philip R Bennett has a patent PCT/GB1997/000529 WO1997031631 A1 ‘COX-2 selective inhibitors for managing labour and uterine contractions’ issued, a patent PCT/GB2004/001380 WO2005053705 A1 ‘Use of a cyclopentenone prostaglandin for delaying the onset and/or preventing the continuation of labour’ (priority date 2 December 2003) issued, a patent PCT/GB2016/050618 ‘Circulating miRNAs predictive of cervical shortening and preterm birth’ (pending UK filing 6 March 2015/full international filing completed 7 March 2016) issued, a patent PCT/GB2016/ 050621 ‘Rapid evaporative ionisation mass spectroscopy (REIMS) and desorbtion electrospray ionisation mass spectroscopy (DESI-MS) analysis of swabs and biopsy samples’ (pending UK filing 6 March 2015/full international filing completed 7 March 2016) pending, a patent PCT/GB2019 ‘Desorbtion electrospray ionisation mass spectroscopy (DESI-MS) analysis of swabs to predict vaginal microbiota’ (pending UK filing March 2019) pending, and a patent PCT/GB2019/ ‘Circulating miRNAs predictive of IUGR’ (pending UK filing March 2019) pending. | en |
| dc.format.extent | 94 | |
| dc.format.extent | 1257192 | |
| dc.identifier | 199314751 | |
| dc.identifier | 785d6282-6814-4e92-a851-c89b7ba6a4f0 | |
| dc.identifier | 85110812749 | |
| dc.identifier | 34219633 | |
| dc.identifier | 85123386614 | |
| dc.identifier.citation | on behalf of the STOPPIT collaborative group 2021, The arabin pessary to prevent preterm birth in women with a twin pregnancy and a short cervix : The STOPPIT 2 RCT. Health Technology Assessment, vol. 25, 44 edn, NIHR Health Technology Assessment programme. https://doi.org/10.3310/hta25440 | en |
| dc.identifier.doi | 10.3310/hta25440 | |
| dc.identifier.isbn | 1366-5278 | |
| dc.identifier.issn | 1366-5278 | |
| dc.identifier.other | ORCID: /0000-0002-1039-5646/work/99292878 | |
| dc.identifier.uri | https://hdl.handle.net/2164/17001 | |
| dc.identifier.url | http://www.scopus.com/inward/record.url?scp=85110812749&partnerID=8YFLogxK | en |
| dc.identifier.vol | 25 | en |
| dc.language.iso | eng | |
| dc.publisher | NIHR Health Technology Assessment programme | |
| dc.relation.ispartofseries | Health Technology Assessment | en |
| dc.subject | SDG 3 - Good Health and Well-being | en |
| dc.subject | R Medicine | en |
| dc.subject | Health Policy | en |
| dc.subject | National Institute for Health Research (NIHR) | en |
| dc.subject | 13/04/22 | en |
| dc.subject.lcc | R | en |
| dc.title | The arabin pessary to prevent preterm birth in women with a twin pregnancy and a short cervix : The STOPPIT 2 RCT | en |
| dc.type | Report | en |
Files
Original bundle
1 - 1 of 1
- Name:
- Norman_etal_HTA_The_Arabin_pessary_VOR.pdf
- Size:
- 1.2 MB
- Format:
- Adobe Portable Document Format